The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance

(2015)   Oncotarget

The role of transient receptor potential vanilloid type-2 ion channels in innate and adaptive immune responses

(2013) Giorgio Santoni et al.   Frontiers in Immunology

Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents

(2012) Massimo Nabissi et al.   CARCINOGENESIS

The transient receptor potential vanilloid-2 cation channel impairs glioblastoma stem-like cell proliferation and promotes differentiation

(2012) Maria Beatrice Morelli et al.   INTERNATIONAL JOURNAL OF CANCER

The Era of Combination Therapy in Myeloma

(2012) Sagar Lonial et al.   JOURNAL OF CLINICAL ONCOLOGY

Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity

(2011) WENZHONG QUE et al.   APMIS

Genomics in Multiple Myeloma

(2011) Nikhil C. Munshi et al.   CLINICAL CANCER RESEARCH

Novel therapies in MM: from the aspect of preclinical studies

(2011) Teru Hideshima et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma

(2011) S. Torres et al.   MOLECULAR CANCER THERAPEUTICS

Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management

(2010) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Classical and/or alternative NF- B pathway activation in multiple myeloma

(2010) Y. N. Demchenko et al.   BLOOD

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

(2010) B. Hoang et al.   BLOOD

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo

(2010) Kihyun Kim et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effects of cannabinoids and cannabinoid-enrichedCannabisextracts on TRP channels and endocannabinoid metabolic enzymes

(2010) Luciano De Petrocellis et al.   BRITISH JOURNAL OF PHARMACOLOGY

TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner

(2010) Massimo Nabissi et al.   CARCINOGENESIS

TRPV2 Activation Induces Apoptotic Cell Death in Human T24 Bladder Cancer Cells: A Potential Therapeutic Target for Bladder Cancer

(2010) Takahiro Yamada et al.   UROLOGY

Non-CB1, Non-CB2 Receptors for Endocannabinoids, Plant Cannabinoids, and Synthetic Cannabimimetics: Focus on G-protein-coupled Receptors and Transient Receptor Potential Channels

(2009) Luciano De Petrocellis et al.   Journal of Neuroimmune Pharmacology

Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin

(2009) P. Frost et al.   MOLECULAR CANCER THERAPEUTICS

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

(2008) Y. Dai et al.   BLOOD

Shared Principles in NF-κB Signaling

(2008) Matthew S. Hayden et al.   CELL

NF-??B in the pathogenesis and treatment of multiple myeloma

(2008) Zhi-Wei Li et al.   CURRENT OPINION IN HEMATOLOGY

TRPV2 Is Activated by Cannabidiol and Mediates CGRP Release in Cultured Rat Dorsal Root Ganglion Neurons

(2008) N. Qin et al.   JOURNAL OF NEUROSCIENCE

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE